BeiGene Corp (ONC) - תחזית צמיחת רווחים לשנה הבאה

BeiGene Ltd (ONC) is implementing AI to accelerate molecule discovery while maintaining strict medical oversight. The company is reducing its dependence on China through the global promotion of its flagship drug. Its strategy for capturing Western markets relies on an accessible clinical base. GURU.Markets quotes drive this chart of analyst EPS growth estimates, where the current value is 19.00.

High capacity utilization and the modernization of BeiGene Ltd (ONC) oncology manufacturing plants determine the future profitability of the business. This indicator measures the expected percentage growth in earnings per share by aggregating forecasts from leading US analysts. Investors use this metric to filter for assets with sustainable capitalization potential. A systematic decline in the consensus net income growth estimate signals risks of investment impairment.